MASTL and cancer: In this study, we delineated the MASTL-ENSA/ARPP19-PP2A/B55 pathway as an important determinant of cisplatin resistance and clinical treatment outcome in OSCC, and validated MASTL inhibition as a potentially valuable therapeutic strategy in combinatorial cancer therapy with cisplatin.